Improving Clinical Trial Performance by Optimizing Protocol Design
(June 19, 2019)
Decisions made in clinical trial protocol design can have significant financial impacts during product development and commercialization. Decisions can influence clinical trial performance in many ways including protocol amendments, patient recruitment, patient retention and compliance as well as the overall timing of the development program. Unfortunately, decision making during protocol authoring sometimes feels like high risk prediction that can affect the clinical trial and the future commercial success of the product.
In this webinar, industry experts will discuss the factors affecting protocol design and decision making and present concrete ways to leverage the power of data and AI to overcome these challenges and optimize protocol design.
- Understand the challenges inherent in Protocol Design today
- Increase understanding of the available data assets and AI capabilities
- Provide insight into how to improve decision making in the protocol design process
PharmD, Deputy Chief Health Officer
IBM Watson Health
Rob DiCicco is currently the Deputy Chief Health Officer at IBM Watson Health. Rob previously served as Vice President of the Clinical Innovation and Digital Platforms Group at GlaxoSmithKline. He was also the Work Stream Leader for the Common Protocol Template Project sponsored by TransCelerate BioPharma and one of the Team Leaders for CTTI's Novel Endpoints Work Stream as part of the mHealth in Clinical Trials Initiative. Rob has more than 25 years of experience in clinical development in a variety of leadership positions in CRO, mid-sized and large pharmaceutical companies. He received his Doctorate of Pharmacy degree at the University of the Sciences of Philadelphia. Over the course of his career he has had a key role in the development of a number of successful new medicines. Rob’s area of expertise includes clinical pharmacology and experimental medicine, innovative clinical trial design, project management and ethics in human research.
Julian Jenkins, PhD
Group Vice President, Development Operations and Project Management
Julian is a Group Vice President and Head of Development Operations and Project Management at the Incyte Corporation in Wilmington, Delaware. His team are accountable for the strategy, planning and execution of Incyte’s oncology, inflammation and autoimmunity clinical portfolio. He has more than 20 years’ experience in the pharmaceutical industry, including a variety of scientific, business and operational leadership roles at GSK, including a number of years as a leader on the TransCelerate Biopharma oversight committee. He is a proud husband and father of four children and a rescued dog. Julian received his PhD from the University of Nottingham Medical School in the UK.
(June 19, 2019)